Chronic myeloid leukemia: Sequencing of TKI therapies

Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an "optimal" outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.

Original languageEnglish (US)
Pages (from-to)164-169
Number of pages6
JournalHematology
Volume2016
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic myeloid leukemia : Sequencing of TKI therapies. / Cortes, Jorge; Kantarjian, Hagop.

In: Hematology, Vol. 2016, No. 1, 01.01.2016, p. 164-169.

Research output: Contribution to journalArticle

Cortes, Jorge ; Kantarjian, Hagop. / Chronic myeloid leukemia : Sequencing of TKI therapies. In: Hematology. 2016 ; Vol. 2016, No. 1. pp. 164-169.
@article{8e24954c6ebf4ea9af6faae3a05f0c44,
title = "Chronic myeloid leukemia: Sequencing of TKI therapies",
abstract = "Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an {"}optimal{"} outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.",
author = "Jorge Cortes and Hagop Kantarjian",
year = "2016",
month = "1",
day = "1",
doi = "10.1182/asheducation-2016.1.164",
language = "English (US)",
volume = "2016",
pages = "164--169",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Chronic myeloid leukemia

T2 - Sequencing of TKI therapies

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an "optimal" outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.

AB - Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an "optimal" outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.

UR - http://www.scopus.com/inward/record.url?scp=85020375225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020375225&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2016.1.164

DO - 10.1182/asheducation-2016.1.164

M3 - Article

C2 - 27913476

AN - SCOPUS:85020375225

VL - 2016

SP - 164

EP - 169

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - 1

ER -